Video

Breast Reconstruction Trainee Assessment

Author(s):

In this podcast, Maisam Fazel, FRCS, MS, MB BChir, discusses his research into a checklist for breast cancer surgeons.

Is there a checklist that can be used along with operating room supervision to assess how well a breast cancer surgeon performs a particular procedure?

Maisam Fazel, FRCS, MS, MB BChir, of Imperial College Healthcare NHS Trust in the United Kingdom, believes it is not only desirable but also possible to shift surgical training toward a competency-based approach. His research on developing an assessment tool for latissimus dorsi breast reconstruction (LDBR) surgery was among the top-scoring abstracts at the Miami Breast Cancer Conference.

Fazel adapted the Objective Structured Assessment of Technical Skill tool used in the UK surgical curriculum to LDBR, creating categories specific to the procedure. He then used the tool to assess 15 breast reconstruction trainees, who were divided into 3 groups of 5 trainees each based on 2, 4, and 7 years of postinternship experience, respectively.

The assessment tool “was able to significantly discriminate between trainees of different seniority,” with more experienced trainees performing better than those with less seniority.

In this podcast, Fazel discusses his research.

Related Videos
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie